Search Results - "Holm, A C"

Refine Results
  1. 1

    Effects of resistance training on quality of life in postmenopausal women with vasomotor symptoms by Berin, E., Hammar, M., Lindblom, H., Lindh-Åstrand, L., Spetz Holm, A.-C.

    “…Most women experience vasomotor symptoms (VMS) around menopause that may affect quality of life negatively. Effective pharmacological treatment exists but is…”
    Get full text
    Journal Article
  2. 2

    Pulmonary embolism in menopausal hormone therapy: a population-based register study by Sundell, M., Spetz Holm, A.-C., Fredrikson, M., Hammar, M., Hoffmann, M., Brynhildsen, J.

    “…Oral but not transdermal menopausal hormone therapy (MHT) increases the risk of venous thromboembolism. There is no evidence regarding the risk of the serious…”
    Get full text
    Journal Article
  3. 3

    Hormone therapy might be underutilized in women with early menopause by Lindh-Åstrand, L., Hoffmann, M., Järvstråt, L., Fredriksson, M., Hammar, M., Spetz Holm, A.-C.

    Published in Human reproduction (Oxford) (01-04-2015)
    “…STUDY QUESTION Are Swedish women age 40–44 years with assumed early menopause ‘undertreated’ by hormone therapy (HT)? SUMMARY ANSWER Many women with probable…”
    Get full text
    Journal Article
  4. 4

    Hot flushes still occur in a population of 85-year-old Swedish women by Vikström, J., Spetz Holm, A-C., Sydsjö, G., Marcusson, J., Wressle, E., Hammar, M.

    “…Abstract Objectives Hot flushes and night sweats often cause discomfort and may negatively affect sleep and quality of life. Studies have shown that menopausal…”
    Get full text
    Journal Article
  5. 5

    Hot flushes, hormone therapy and alternative treatments: 30 years of experience from Sweden by Lindh-Åstrand, L., Hoffmann, M., Hammar, M., Spetz Holm, A.-C.

    “…Abstract Objectives The use of hormone therapy (HT) for hot flushes has changed dramatically over the past five decades. In this cross-sectional questionnaire…”
    Get full text
    Journal Article
  6. 6

    Cortisol in saliva--reference ranges and relation to cortisol in serum by Aardal, E, Holm, A C

    “…The aim of this study was to establish morning and evening reference ranges for cortisol in saliva. Another objective was to compare the concentrations of the…”
    Get more information
    Journal Article
  7. 7

    Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication by Mölgaard, J, Malinow, M R, Lassvik, C, Holm, A C, Upson, B, Olsson, A G

    Published in Journal of internal medicine (01-03-1992)
    “…The aim of this study was to test the question of hyperhomocyst(e)inaemia as a risk factor for intermittent claudication (IC) independent of other important…”
    Get more information
    Journal Article
  8. 8

    Salivary cortisol--an alternative to serum cortisol determinations in dynamic function tests by Aardal-Eriksson, E, Karlberg, B E, Holm, A C

    Published in Clinical chemistry and laboratory medicine (30-04-1998)
    “…Salivary cortisol was measured as an alternative to serum cortisol as a marker for adrenocortical function following insulin tolerance test,…”
    Get more information
    Journal Article
  9. 9

    Salivary cortisol and serum prolactin in relation to stress rating scales in a group of rescue workers by Aardal-Eriksson, Elisabeth, Eriksson, Thomas Erik, Holm, Ann-Charlotte, Lundin, Tom

    Published in Biological psychiatry (1969) (15-09-1999)
    “…Background: Rescue service personnel are often exposed to traumatic events as part of their occupation, and higher prevalence rates of psychiatric illness have…”
    Get full text
    Journal Article
  10. 10

    Experiences of long-term treatment with remoxipride: efficacy and tolerability by Wålinder, J, Holm, A C

    “…An international clinical trial programme was undertaken to evaluate the clinical safety and tolerability of remoxipride during a 12 month long-term study and…”
    Get more information
    Journal Article
  11. 11

    Alaproclate, a new selective 5-HT uptake inhibitor with therapeutic potential in depression and senile dementia by ÖGREN, S.-O, HOLM, A.-C, HALL, H, LINDBERG, U. H

    Published in Journal of Neural Transmission (01-01-1984)
    “…Alaproclate, a new specific 5-HT uptake inhibitor, was examined for its action on several receptors in the brain, for its action on the NA, DA and 5-HT uptake…”
    Get full text
    Journal Article
  12. 12

    Menopausal vasomotor symptoms and subclinical atherosclerotic cardiovascular disease by Nilsson, S, Qvick, A, Henriksson, M, Sederholm Lawesson, S, Spetz Holm, A C, Leander, K

    Published in EUROPEAN HEART JOURNAL (09-11-2023)
    “…Abstract Background Menopausal vasomotor symptoms (VMS) have been associated with subclinical and manifest atherosclerotic cardiovascular disease (ASCVD) but…”
    Get full text
    Journal Article Conference Proceeding
  13. 13

    Kinetics of triiodothyronine uptake by erythrocytes in hyperthyroidism, hypothyroidism, and thyroid hormone resistance by Holm, A C, Kågedal, B

    “…We studied the initial uptake of L-T3 in erythrocytes isolated from normal subjects and patients with abnormal thyroid function. The uptake was saturable, with…”
    Get more information
    Journal Article
  14. 14

    Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia by Ogren, S O, Holm, A C

    Published in Journal of Neural Transmission (01-12-1980)
    “…The effects of the specific 5-HT uptake inhibitors alaproclate and zimelidine, the 5-HT releasing compound p-chloroamphetamine (PCA) and the specific NA uptake…”
    Get full text
    Journal Article
  15. 15

    Tolerability of remoxipride in the long term treatment of schizophrenia : an overview by HOLM, A.-C, EDSMAN, I, LUNDBERG, T, ODLIND, B

    Published in Drug safety (01-06-1993)
    “…506 patients with schizophrenia, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria, were included in a long term…”
    Get full text
    Journal Article
  16. 16

    P4635Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapy by Holm, A C, Henriksson, M, Alfredsson, J, Janzon, M, Johansson, T, Swahn, E, Vial, D, Sederholm Lavesson, S

    Published in European heart journal (01-10-2019)
    “…Abstract Background Triple antithrombotic therapy (TAT) is known to increase bleeds and its relevance is questioned. No study has observed the long-term risk…”
    Get full text
    Journal Article
  17. 17

    Mitogenic activity of glia maturation factor. Interaction with insulin and insulin-like growth factor-II by Lim, R, Miller, J F, Hicklin, D J, Holm, A C, Ginsberg, B H

    Published in Experimental cell research (01-08-1985)
    “…The mitogenic activity of glia maturation factor (GMF) was tested on sparse-cultured cells. GMF stimulates the growth rate of normal astroblasts and…”
    Get more information
    Journal Article
  18. 18

    Active transport of L-tri-iodothyronine through the red cell plasma membrane--true or false? by Holm, A C

    “…The membrane transport of L-tri-iodothyronine has been studied in human erythrocyte ghosts. Initial uptake showed saturability with a Km of 33.8 nmol/l,…”
    Get more information
    Journal Article
  19. 19

    The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor by Ogren, S O, Ross, S B, Hall, H, Holm, A C, Renyi, A L

    “…Zimelidine (ZIM) and its main active metabolite norzimelidine (NZIM) have been shown to preferentially inhibit 5-hydroxytryptamine (5-HT) neuronal uptake both…”
    Get more information
    Journal Article
  20. 20